A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

US biotech PTC Therapeutics released mixed new data on its Phase II trial of PCT187 (votoplam) in Huntington’s disease. UK ...

Eli Lilly and Company (NYSE: LLY) and Purdue University announced Friday (May 9) a significant expansion of their ...

Eli Lilly and Purdue University announced a $250 million in what the two institutions say is the largest industry-academic partnership in the country.

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, raised a $130 million Series B round.